NXG 📈 NexgenRX - Overview
Exchange: V • Country: Canada • Currency: CAD • Type: Common Stock • ISIN: CA65337X1042
NXG: Claims, Management, Administration, Programs, Services, Healthcare, Benefits
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. It offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. The company also provides ancillary services. TNexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada. Web URL: https://www.nexgenrx.com
Additional Sources for NXG Stock
NXG Stock Overview
| Market Cap in USD | 13m |
| Sector | Healthcare |
| Industry | Healthcare Plans |
| GiC Sub-Industry | Managed Health Care |
| IPO / Inception |
NXG Stock Ratings
| Growth 5y | 33.8% |
| Fundamental | 11.3% |
| Dividend | 18.3% |
| Rel. Strength Industry | 2906 |
| Analysts | - |
| Fair Price Momentum | 0.27 CAD |
| Fair Price DCF | 0.49 CAD |
NXG Dividends
| Dividend Yield 12m | 1.79% |
| Yield on Cost 5y | 2.78% |
| Annual Growth 5y | -20.63% |
| Payout Consistency | 86.3% |
NXG Growth Ratios
| Growth Correlation 3m | -9.4% |
| Growth Correlation 12m | 67.6% |
| Growth Correlation 5y | 20.2% |
| CAGR 5y | 9.28% |
| CAGR/Mean DD 5y | 0.36 |
| Sharpe Ratio 12m | 0.54 |
| Alpha | 1.43 |
| Beta | 0.69 |
| Volatility | 0.04% |
| Current Volume | 0k |
| Average Volume 20d | 2.9k |
What is the price of NXG stocks?
As of January 03, 2025, the stock is trading at CAD 0.28 with a total of 0 shares traded.
Over the past week, the price has changed by +3.70%, over one month by -1.55%, over three months by +18.95% and over the past year by +21.11%.
As of January 03, 2025, the stock is trading at CAD 0.28 with a total of 0 shares traded.
Over the past week, the price has changed by +3.70%, over one month by -1.55%, over three months by +18.95% and over the past year by +21.11%.
Is NexgenRX a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, NexgenRX is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 11.34 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NXG as of January 2025 is 0.27. This means that NXG is currently overvalued and has a potential downside of -3.57%.
Neither. Based on ValueRay Fundamental Analyses, NexgenRX is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 11.34 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NXG as of January 2025 is 0.27. This means that NXG is currently overvalued and has a potential downside of -3.57%.
Is NXG a buy, sell or hold?
NexgenRX has no consensus analysts rating.
NexgenRX has no consensus analysts rating.
What are the forecast for NXG stock price target?
According to ValueRays Forecast Model, NXG NexgenRX will be worth about 0.3 in January 2026. The stock is currently trading at 0.28. This means that the stock has a potential upside of +7.14%.
According to ValueRays Forecast Model, NXG NexgenRX will be worth about 0.3 in January 2026. The stock is currently trading at 0.28. This means that the stock has a potential upside of +7.14%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 4.3 | 1417.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 0.3 | 7.1% |